Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance.
Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H???O???-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-??B signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.
Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance.
Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H???O???-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-??B signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
